Intralytix Receives FDA Regulatory Clearance for Phage-Based Shigella Technology

Friday, April 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

BALTIMORE, April 7, 2017 /PRNewswire/ -- Intralytix, Inc. announced today that its latest food safety product, ShigaShield™,

has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

ShigaShield™ is a non-chemical antimicrobial preparation for controlling the foodborne/waterborne bacterial pathogen Shigella. The

active ingredients of ShigaShield™ are naturally occurring lytic bacteriophages that selectively and specifically kill Shigella species, including strains belonging to the three major disease-causing species of Shigella: S. flexneri, S. sonnei and S. dysenteriae.

"Shigella is one of the leading bacterial causes of diarrhea worldwide, causing an estimated 80-165 million cases each year," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist. "In the United States, Shigella is the third most common causes of gastroenteritis, with more than 500,000 cases occurring annually. ShigaShield™ can help reduce the incidence or severity of such illnesses." Dr. Sulakvelidze added, "Another important potential application is to use ShigaShield™ for improving the safety of foods for the US military and for travelers; for example, for treating fresh fruits and vegetables in high risk Shigella locations oversees where the local sanitation standards and/or quality of water are not optimal, thus creating an increased risk of Shigella contamination."

Intralytix is a world leader in the development of bacteriophage-based products for food safety. The company already has three FDA/USDA approved phage-based products on the market: (1) ListShield™, effective at substantially reducing or eliminating Listeria monocytogenes in food products, (2) EcoShield™, effective at substantially reducing or eliminating E. coli O157:H7 in red meat intended for grinding, and (3) SalmoFresh™, effective at substantially reducing or eliminating Salmonella in poultry, fish, shellfish, and fresh and processed fruits and vegetables.

Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health and human therapeutics and probiotics.

For more information, contact Mr. John Woloszyn (410-625-3813 or jwoloszyn@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 or asulakvelidze@intralytix.com).

Intralytix, Inc.Columbus Center701 E. Pratt StreetBaltimore, Maryland 21202Safety by Nature™Web site: www.Intralytix.com1-877-ITXPHAGE (1-877-489-7424)

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intralytix-receives-fda-regulatory-clearance-for-phage-based-shigella-technology-300436440.html

SOURCE Intralytix, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook